Back

Find the FamiCord brand in your country

Free guide

Smart Cells free guide

Download

Transplant stories

Real Treatments. Real Families. Real Hope.

Smart Cells was the first private UK stem cell bank to release samples for transplant — proving that family cord blood banking is not just about storage, but about delivering real therapies when they are needed most.

Why Stem Cell Transplants Matter

At some point in life, your child or family member may need access to stem cell therapy. Today, these treatments are being used for:

  • Blood cancers such as leukaemia and lymphoma
  • Inherited genetic disorders including thalassemia and sickle cell disease
  • Neurological conditions such as cerebral palsy and brain injury
  • Immune deficiencies and metabolic disorders
  • Emerging therapies for sports injuries, inflammatory conditions, and skin repair

By preserving your baby’s umbilical cord blood and tissue, you safeguard access to these life-saving and life-enhancing possibilities.

Proven Track Record

Smart Cells has released more stem cell samples for treatment than any other private UK bank, with a 100% success rate for every sample delivered to clinicians worldwide.

These samples have helped children and families across the globe face illnesses such as:

  • Cerebral Palsy
  • Thalassemia
  • Leukaemia
  • HSV Encephalitis
  • Immune system disorders

Each transplant is more than a statistic — it represents a child given new options, and a family given hope.

A Milestone for Families and for Science

Every successful release shows how far the field of stem cell research has advanced. What was once only a possibility is now a proven therapy.

Yet many parents are still unaware of the benefits of storing their baby’s cord blood and tissue. Smart Cells is working to change that — by raising awareness, sharing real transplant stories, and supporting research into the next generation of regenerative treatments.

Powered by FamiCord: Europe’s Stem Cell Leader in banking and use of cells

As part of the FamiCord Group, Europe’s largest family stem cell bank and one of the world’s top three:

  • Families gain access to 1,000,000+ stored cord blood units across the network
  • Therapies are supported by specialist research centres and clinical teams in 35+ countries including FamiCord Programme for brain disorders
  • FamiCordTx, the group’s advanced therapies division, is actively developing new cell-based treatments to extend the possibilities for families everywhere

Together, Smart Cells and FamiCord stand at the forefront of innovation, offering parents confidence today — and hope for tomorrow.

FamiCord Group releases

Patients

7800+

Expand table
No. Source Source type Diagnosis Medical sector Year of application Therapy Country Age of the recipient
1 Skeletal Muscle Allogeneic – Related Duchenne Muscular Dystrophy (DMD) Genetic Disorder 2026 Experimental Therapy Poland 14
2 Cord Tissue Allogeneic – Related Autism Neurology 2026 Experimental Therapy Slovakia 4
3 Cord Tissue Autologous Autism Neurology 2026 Experimental Therapy Slovakia 4
4 Cord Tissue Allogeneic – Unrelated Autism Neurology 2026 Experimental Therapy Poland 7,11
5 Cord Tissue Allogeneic – Unrelated Autism Neurology 2026 Experimental Therapy Poland 5,3
6 Cord Tissue Allogeneic – Unrelated Autism Neurology 2026 Experimental Therapy Poland 7,11
7 Cord Tissue Allogeneic – Unrelated Cerebral Palsy Neurology 2026 Experimental Therapy Poland 3,11
8 Cord Tissue Allogeneic – Unrelated Cartilage Lesions Orthopedics 2026 Experimental Therapy Poland 67,2
9 Cord Tissue Allogeneic – Unrelated Cartilage Lesions Orthopedics 2026 Experimental Therapy Poland 50,7
10 Cord Tissue Allogeneic – Unrelated Cerebral Palsy Neurology 2026 Experimental Therapy Poland 4,6
11 Cord Tissue Allogeneic – Unrelated Cerebral Palsy Neurology 2026 Experimental Therapy Poland 6,5
12 Cord Tissue Allogeneic – Unrelated Cerebral Palsy Neurology 2026 Experimental Therapy Poland 6,7
13 Cord Tissue Allogeneic – Unrelated Cerebral Palsy Neurology 2026 Experimental Therapy Poland 6,5
14 Cord Tissue Allogeneic – Unrelated GvHD Hematology 2026 Experimental Therapy Poland 2,9
15 Cord Tissue Allogeneic – Unrelated Cerebral Palsy Neurology 2026 Experimental Therapy Poland 3,1
16 Cord Tissue Allogeneic – Unrelated Cartilage Lesions Orthopedics 2026 Experimental Therapy Poland 60,7
17 Cord Tissue Allogeneic – Unrelated GvHD Hematology 2026 Experimental Therapy Poland 5,5
18 Cord Tissue Allogeneic Autism Neurology 2026 Experimental Therapy United Arab Emirates 6
19 Cord Tissue Allogeneic – Unrelated GvHD Hematology 2026 Experimental Therapy Poland 4,1
20 Cord Tissue Allogeneic – Unrelated Cerebral palsy Neurology 2026 Experimental Therapy Poland 4,9
21 Cord Tissue Allogeneic – Unrelated Autism Neurology 2026 Experimental Therapy Poland 8,7
22 Cord Tissue Allogeneic – Unrelated Cerebral palsy Neurology 2026 Experimental Therapy Poland 3,2
23 Cord Tissue Autologous Cerebral Palsy Neurology 2026 Experimental Therapy Slovakia 2
24 Cord Tissue Allogeneic – Related Autism Neurology 2026 Experimental Therapy Slovakia 6
25 Cord Tissue Allogeneic – Related Autism Neurology 2026 Experimental Therapy Slovakia 13
26 Cord Tissue Allogeneic – Related Autism Neurology 2026 Experimental Therapy Slovakia 8
27 Cord Tissue Allogeneic – Related Autism Neurology 2026 Experimental Therapy Slovakia 9
28 Cord Tissue Autologous Autism Neurology 2026 Experimental Therapy Slovakia 8
29 Cord Tissue Autologous Autism Neurology 2026 Experimental Therapy Slovakia 5
30 Cord Tissue Autologous Autism Neurology 2026 Experimental Therapy Slovakia 3
31 Cord Tissue Allogeneic – Related Autism Neurology 2026 Experimental Therapy Slovakia 3
32 Cord Tissue Allogeneic – Unrelated Autism Neurology 2026 Experimental Therapy Poland 7,1
33 Cord Tissue Allogeneic – Unrelated Optic Atrophy Ophthalmology 2026 Experimental Therapy Poland 76,3
34 Cord Tissue Allogeneic – Unrelated Encephalitis, Myelitis Neurology 2026 Experimental Therapy Poland 36,6
35 Cord Tissue Allogeneic – Unrelated Stress Incontinence Urology 2026 Experimental Therapy Poland 62,4
36 Cord Tissue Allogeneic – Unrelated aGvHD, PNH Hematology 2026 Experimental Therapy Poland 17,8
37 Cord Tissue Allogeneic – Unrelated Progressive Bulbar Palsy Neurology 2026 Experimental Therapy Poland 58,1
38 Cord Tissue Allogeneic – Unrelated Autism Neurology 2026 Experimental Therapy Poland 6,2
39 Cord Tissue Allogeneic – Unrelated Spinocerebellar Ataxia Neurology 2026 Experimental Therapy Poland 59,4
40 Cord Tissue Allogeneic – Unrelated aGvHD Hematology 2026 Experimental Therapy Poland 15,5
41 Cord Tissue Allogeneic – Unrelated aGvHD Hematology 2026 Experimental Therapy Poland 12,1
42 Cord Tissue Allogeneic – Unrelated aGvHD Hematology 2026 Experimental Therapy Poland 10
43 Cord Tissue Allogeneic – Unrelated MSA, Multiple System Atrophy Neurology 2026 Experimental Therapy Centrum Medyczne Klara Częstochowa 53,1
44 Cord Tissue Allogeneic – Unrelated Stress Incontinence Gynecology 2026 Experimental Therapy Szpital Uniwersytecki w Krakowie ul. Mikołaja Kopernika 79,11
45 Cord Tissue Allogeneic – Unrelated Progressive Bulbar Palsy Neurology 2026 Experimental Therapy Centrum Medyczne Klara Częstochowa 65,1
46 Cord Tissue Allogeneic – Unrelated MSA, Multiple System Atrophy Neurology 2026 Experimental Therapy Centrum Medyczne Klara Częstochowa 61,3
47 Cord Tissue Allogeneic Related Spondylosis + Lumbar Disc Disease Rheumatology 2026 Experimental Therapy Slovakia , Malacky 32
48 Cord Tissue Autologus Autism Neurology 2026 Experimental Therapy Slovakia , Malacky 3
49 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Poland 4,6
50 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Poland 8,9
51 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Poland 5,2
52 Cord Blood Allogeneic – Unrelated Acute Leukemia in remission, Pancytopenia after treatment Hematology 2026 Standard Therapy Denmark 18, 6
53 Cord Blood Allogeneic – Related Juvenile Myelomonocytic Leukemia (JMML) Hematology 2026 Standard Therapy Germany 10, 10
54 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Poland 6,9
55 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Poland 7,2
56 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Poland 5,5
57 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Poland 4,1
58 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Poland 8,6
59 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Slovakia 7,6
60 Cord Blood Allogeneic Thalassemia Major Hematology 2026 Standard Therapy Turkey 7,8
61 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Poland 8,9
62 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Slovakia 4,5
63 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Poland 3,5
64 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Slovakia 8
65 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Slovakia 5
66 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Slovakia 3
67 Cord Blood Autologous Autism Neurology 2026 Experimental Therapy Poland 6,5
68 Cord Blood Allogeneic – Related Diamond-Blackfan Anemia (DBA) Hematology 2026 Standard Therapy Germany 10, 1
69 Cord Blood Autologus Autism Neurology 2026 Experimental Therapy Poland, Lublin, Uniwersytecki Szpital Kliniczny 7,11
70 Cord Blood Autologus Autism Neurology 2026 Experimental Therapy Poland, Lublin, Uniwersytecki Szpital Kliniczny 7,4
71 Cord Blood Autologus Autism Neurology 2026 Experimental Therapy Slovakia , Malacky 3
72 Bone Marrow Family Allogeneic T-Cell Lymphoma Hematology 2026 Standard Therapy Netherlands 65
73 Bone Marrow Family Allogeneic Other Malignancy Hematology 2026 Standard Therapy France 51
74 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Italy 27
75 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy France 14
76 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy France 68
77 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy United Kingdom 43
78 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 68
79 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 69
80 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 67
81 Bone Marrow Family Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 64
82 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 73
83 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy United Kingdom 26
84 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 74
85 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Netherlands 66
86 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Romania 25
87 Bone Marrow Family Allogeneic Other Myelofibrosis/Myelosclerosis Hematology 2026 Standard Therapy USA 65
88 Bone Marrow Family Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Poland 62
89 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 63
90 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Netherlands 47
91 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Czechia 67
92 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Sweden 74
93 Bone Marrow Family Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 72
94 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Ukraine 40
95 Bone Marrow Family Allogeneic No Data Hematology 2026 Standard Therapy Germany 70
96 Bone Marrow Family Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Hungary 35
97 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 71
98 Bone Marrow Family Allogeneic Primary Myelofibrosis Hematology 2026 Standard Therapy Poland 37
99 Bone Marrow Family Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy France 68
100 Bone Marrow Family Allogeneic Fanconi Anemia Hematology 2026 Standard Therapy Germany 4
Expand table

Stem cell transplantation has become an established procedure

700,000

cord blood collections have been undertaken globally

50,000

hematopoietic stem cell transplants take place every year

400/500

of these transplants are in Europe

Our transplant stories

Smart Cells have released 24 UK
samples to six countries.

Stem cells hold the key to more than 80 life-changing treatments, with clinical trials underway on many more. Replacing damaged cells and tissue, they can even save a child’s life.

Icon

100% infusion success rate

For samples released for transplant.

Icon

3 months – 12 yrs old

Stored cord blood samples have been successfully released for use in transplant for children aged as little as 3 months to 12 years old.

Icon

46% self | 54% siblings

Smart Cells have successfully released stored cord blood samples that have been used for treatment with the child it was collected from and also siblings.

Smart Cells releases

UK samples released

24

Expand table
Sample release date Medical condition Recipient relationship Age of the recipient Unit volume Medical center Country
2005.11 Thalassemia Allogeneic (Sibling) 4 Years 144ml Mount Vernon Hospital Singapore
2005.11 Leukaemia Allogeneic (Sibling) Restricted Restricted Stem Cells and Immunology Department, Birmingham UK
2007.02 Thalassemia Allogeneic (Sibling) 7 Years 76ml Kinderlink der Tu Munchen Germany
2009.08 Cerebral Palsy Autologous (Self) 3 Years 51ml Duke University, North Carolina USA
2010.01 Cerebral Palsy Autologous (Self) 3 Years 81ml Duke University, North Carolina USA
2013.10 Thalassemia Allogeneic (Sibling) 5 Years 58ml Catherine Lewis Centre, Hammersmith UK
2014.01 Leukaemia Allogeneic (Sibling) 4 Years 71ml Medizinische Hochschule, Hanover Germany
2014.05 Cerebral Palsy Autologous (Self) 1 year 68ml Duke University, North Carolina USA
2014.06 HSV Encephalitis & NMDA Receptor Antibody Virus Autologous (Self) 2 Years 57ml Duke University, North Carolina USA
2014.08 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 3 Months 39ml Duke University, North Carolina USA
2015.02 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 6 Months 53ml Duke University, North Carolina USA
2015.03 Severe Combined Immune Deficiency Autologous (Self) 3 Months 74ml Duke University, North Carolina USA
2015.03 Sickle Cell Disease Allogeneic (Sibling) 2 .5 Years 57ml BLK Hospital, New Delhi India
2015.11 Thalassemia Allogeneic (Sibling) 12 Years 87ml Children’s Hospital of Pittsburgh of UPMC USA
2016.03 Cerebral Palsy Allogeneic (Sibling) 6 Years 101ml Duke University, North Carolina USA
2017.04 Lymphoblastic Leukaemia (^1) N/A (Identical twin girls) Restricted 125ml Bambin Gesu Childrens’ Hospital, Rome Italy
2017.06 Cerebral Palsy Autologous (Self) 7 Years 82ml Duke University, North Carolina USA
2017.06 Cerebral Palsy Autologous (Self) 3.4 Years 132ml Duke University, North Carolina USA
2018.03 Autism Autologous (Self) 5.4 Years 73ml Duke University, North Carolina USA
2018.03 Cerebral Palsy Autologous (Self) 3.4 years 132ml Duke University, North Carolina USA
2019.06 Cerebral Palsy Allogeneic (Sibling) 3 Years 104ml Duke University, North Carolina USA
2022.02 Cerebral Palsy Allogeneic (Sibling) 11 Years 185ml Duke University, North Carolina USA
2023.08 Cerebral Palsy Allogeneic (Sibling) 3 Years 46ml Duke University, North Carolina USA
2024.01 Thalassaemia Allogeneic (Sibling) 8 Years 45ml Cincinnati Children’s Hospital Medical Center USA
Expand table
Icon

Ready to get started or need more information?